[go: up one dir, main page]

WO1998056810A2 - Proteine humaine lus-i, sa production et son utilisation - Google Patents

Proteine humaine lus-i, sa production et son utilisation Download PDF

Info

Publication number
WO1998056810A2
WO1998056810A2 PCT/EP1998/003460 EP9803460W WO9856810A2 WO 1998056810 A2 WO1998056810 A2 WO 1998056810A2 EP 9803460 W EP9803460 W EP 9803460W WO 9856810 A2 WO9856810 A2 WO 9856810A2
Authority
WO
WIPO (PCT)
Prior art keywords
cys
thr
ser
ala
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP1998/003460
Other languages
German (de)
English (en)
Other versions
WO1998056810A3 (fr
Inventor
Wolf-Georg Forssmann
Gabriele Heine
Knut Adermann
Peter Schulz-Knappe
Michael Nehls
Markus Meyer
Klaus Bensch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE1997149073 external-priority patent/DE19749073C1/de
Application filed by Individual filed Critical Individual
Priority to AU85366/98A priority Critical patent/AU8536698A/en
Publication of WO1998056810A2 publication Critical patent/WO1998056810A2/fr
Publication of WO1998056810A3 publication Critical patent/WO1998056810A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • This disulfide pattern was obtained by proteolytic cleavage with various endoproteases and sequencing of the fragments obtained.
  • the corresponding fragments were sequenced by a combination of electrospray mass spectroscopy and Edman protein sequencing. Both human hemofiltrate and urine-derived LUS-I had identical chromatographic properties, molecular weights, and disulfide patterns.
  • a further embodiment of the invention is represented by pharmaceutical compositions which contain the peptides according to the invention in a pharmaceutical dosage form.
  • the preferred amount of the peptides according to the invention to be administered is between 1 ⁇ g and 1 g per dose unit when 1 to 5 doses of the drug are administered per day.
  • nucleic acids which code for the peptides according to the invention can derive nucleic acids which code for the peptides according to the invention from the sequence of the peptides according to the invention using the genetic code. For expression in recombinant organisms, those codons are chosen which correspond to the codon usage of the transformed organism.
  • Antisense nucleotides i.e. Nucleotides which bind to the nucleic acid sequences according to the invention under stringent conditions have, in particular, those sequences which can bind to parts of the mRNA in the target system.
  • the person skilled in the art can determine the sequence of the mRNA from the peptide sequence using known methods.
  • Antibodies that bind to the peptides according to the invention can be obtained in a simple manner by immunizing animals become.
  • the peptides are optionally injected into the animals together with other auxiliary substances at intervals of several weeks, and then antibodies are isolated from the blood.
  • Preferred animals for this are rabbits and mice.
  • Known methods can be used to obtain immortal cells from the antibody-producing mouse cells, which allow the production of monoclonal antibodies.
  • the transgenic mammals according to the invention with gene efficiency LUS-1 are obtained by methods known to the person skilled in the art. In general, the homologous recombination between DNA sequences is used. The vectors required for this can be constructed in a simple manner if the gene sequence is known. If the mRNA sequence is known, the gene can be found, for example, likewise by means of a polymerase chain reaction, and the amplified gene fragment can be elucidated by means of sequencing.
  • the proteins, nucleic acids and antisense nucleotides, antibodies and inhibitors according to the invention are suitable for the production of diagnostic agents.
  • the antibodies in particular enable the expression of the protein according to the invention to be determined in tissue or body fluids, for example by means of an immunoassay such as the known ELISA.
  • an immunoassay such as the known ELISA.
  • the nucleic acids according to the invention it can be analyzed - by means of amplification reactions such as polymerase chain reactions - whether there are gene diseases which can then be treated with the help of the medicaments according to the invention.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne une protéine présentant la séquence d'acides aminés de SEQ ID N° 1: NH2-Leu-Lys-Cys-Tyr-Thr- Cys-Lys-Glu-Pro-Met- Thr-Ser-Ala-Ser-Cys-Arg- Thr-Ile-Thr-Arg- Cys-Lys-Pro-Glu-Asp-Thr- Ala-Cys-Met-Thr-Thr-Leu- Val-Thr-Val-Glu-Ala-Glu- Tyr-Pro-Phe- Asn-Gln-Ser-Pro- Val-Val-Thr-Arg- Ser-Cys-Ser-Ser- Ser-Cys-Val-Ala-Thr- Asp-Pro-Asp-Ser- Ile-Gly-Ala-Ala- His-Leu-Ile-Phe- Cys-Cys-Phe-Arg- Asp-Leu-Cys-Asn- Ser-Glu-Leu-COOH (LUS-I). Elle concerne également ses dérivés cycliques, glycosylés, phosphorylés, acétylés, amidés et/ou contenant des liaisons de chaînes latérales, ainsi que des fragments présentant l'activité biologique de LUS-I.
PCT/EP1998/003460 1997-06-09 1998-06-09 Proteine humaine lus-i, sa production et son utilisation Ceased WO1998056810A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU85366/98A AU8536698A (en) 1997-06-09 1998-06-09 Lus-1 human protein, its production and use

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE19724301.0 1997-06-09
DE19724301 1997-06-09
DE1997149073 DE19749073C1 (de) 1997-11-06 1997-11-06 Humanes ANUP (humanes Anti-Neoplastisches-Urin-Peptid), seine Herstellung und Verwendung
DE19749073.5 1997-11-06

Publications (2)

Publication Number Publication Date
WO1998056810A2 true WO1998056810A2 (fr) 1998-12-17
WO1998056810A3 WO1998056810A3 (fr) 1999-03-11

Family

ID=26037290

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1998/003460 Ceased WO1998056810A2 (fr) 1997-06-09 1998-06-09 Proteine humaine lus-i, sa production et son utilisation

Country Status (2)

Country Link
AU (1) AU8536698A (fr)
WO (1) WO1998056810A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004091646A3 (fr) * 2003-04-16 2004-12-16 Univ Lausanne Compositions de slurp-1 et leurs methodes d'utilisation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5298604A (en) * 1992-07-27 1994-03-29 Sloane Nathan H Parital primary amino acid sequence of the antineoplastic protein (ANUP); a cytokine present in granulocytes
IT1257184B (it) * 1992-12-22 1996-01-10 Applied Research Systems Preparato ad attivita' antinfiammatoria, anticoagulante e antitumorale

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004091646A3 (fr) * 2003-04-16 2004-12-16 Univ Lausanne Compositions de slurp-1 et leurs methodes d'utilisation
JP2006523678A (ja) * 2003-04-16 2006-10-19 アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ Ｓｌｕｒｐ−１組成物及びその使用方法
US7135454B2 (en) 2003-04-16 2006-11-14 Applied Research Systems Ars Holding N.V. Use of SLURP-1 compositions for treating schizophrenia
AU2004229237B2 (en) * 2003-04-16 2009-06-04 Merck Serono Sa Use of SLURP-1 for treating diseases related to acetylcholine receptors dysfunction
US7691808B2 (en) 2003-04-16 2010-04-06 Merck Serono Sa Use of Slurp-1 for treating diseases related to acetylcholine receptor dysfunction
NO337494B1 (no) * 2003-04-16 2016-04-25 Merck Serono Sa Sammensetninger som omfatter en effektiv mengde Slurp-1 for anvendelse i behandling av nevrologiske forstyrrelser og hudsykdommer

Also Published As

Publication number Publication date
WO1998056810A3 (fr) 1999-03-11
AU8536698A (en) 1998-12-30

Similar Documents

Publication Publication Date Title
EP1027440B1 (fr) Proteine inhibitrice de la voie de signalisation wnt
KR910002692B1 (ko) 수정 호르몬의 제조방법
Terry et al. The cDNA sequence coding for prepro-PGS (prepro-magainins) and aspects of the processing of this prepro-polypeptide.
DE69727589T2 (de) Mutanten des KERATINOCYTEN-WACHSTUMSFAKTOR-2 (KGF-2 ODER FIBROBLASTENWACHSTUMSFAKTOR-12,FGF-12)
DE19757250A1 (de) Insulin-like growth factor binding protein und seine Verwendung
DE69033200T2 (de) Wundbehandlung mittels biologisch aktiver peptide
JPH05500211A (ja) 造巨核球因子
EP3530667B1 (fr) Peptide à efficacité anti-obésité et anti-diabétique et son utilisation
EP0736095B1 (fr) Cytokine humaine circulante cc-1
JPS6270398A (ja) ウシインタ−ロイキン−２遺伝子のクロ−ニングおよび同定
WO2001034640A2 (fr) Peptide inhibiteur de virus circulant chez l'homme (virip) et son utilisation
WO1998056810A2 (fr) Proteine humaine lus-i, sa production et son utilisation
DE3884853T2 (de) Angiogenininhibitoren.
JPH04500603A (ja) クローン化腎炎抗原
DE10027383A1 (de) Nukleinsäure-Molekül umfassend eine für ein Chemokin, einen Neuropeptid-Präkursor oder mindestens ein Neuropeptid kodierende Nukleinsäuresequenz
KR101025352B1 (ko) 생리활성 복합체
US5440022A (en) Hepatokine and methods for its use
EP0612349B1 (fr) Nouvelle proteine inhibitrice de la trombine isolee dans les reduves
AU783373B2 (en) Epithelial cell growth inhibitors
DE3781017T2 (de) Cytotoxische zusammensetzung aus "killer"-zellen.
DE69832447T2 (de) Gen kodierend für Afadin-1
EP0609242B1 (fr) Nouvelle proteine inhibitrice de la thrombine provenant de tiques
CN1244584A (zh) 具有免疫细胞趋化和造血刺激活性的趋化因子
US20040115191A1 (en) Method for treating psoriasis
DE19749073C1 (de) Humanes ANUP (humanes Anti-Neoplastisches-Urin-Peptid), seine Herstellung und Verwendung

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AU BA BB BG BR CA CN CU CZ EE GE GW HU ID IL IS JP KP KR LC LK LR LT LV MG MK MN MX NO NZ PL RO SG SI SK SL TR TT UA US UZ VN YU

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AU BA BB BG BR CA CN CU CZ EE GE GW HU ID IL IS JP KP KR LC LK LR LT LV MG MK MN MX NO NZ PL RO SG SI SK SL TR TT UA GH

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 1999501578

Format of ref document f/p: F

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA